GLAXF - Orchard Therapeutics: A Leading Gene Therapy Company For Your Watchlist
Orchard Therapeutics (ORTX) is an undercovered, $1.7bn London-headquartered company positioning itself to be the market leader in next-generation, cryopreserved, easily accessible, lentiviral vector based gene therapy. The company originally had 2 gene therapy assets. In 2018, Orchard Therapeutics got into a deal with GlaxoSmithKline (GSK) whereby, against a 20% stake in the company and a seat on its board for GSK, ORTX acquired the entire rare disease gene therapy pipeline of GSK. ORTX is currently running 7 programs through various stages of trial; one, Strimvelis, was already approved through GSK. Strimvelis